NO974119L - Fremgangsmåte for isolering av galantamin - Google Patents

Fremgangsmåte for isolering av galantamin

Info

Publication number
NO974119L
NO974119L NO974119A NO974119A NO974119L NO 974119 L NO974119 L NO 974119L NO 974119 A NO974119 A NO 974119A NO 974119 A NO974119 A NO 974119A NO 974119 L NO974119 L NO 974119L
Authority
NO
Norway
Prior art keywords
galantamine
isolating
extraction
instance
extract
Prior art date
Application number
NO974119A
Other languages
English (en)
Other versions
NO974119D0 (no
NO316380B1 (no
Inventor
Thomas Hille
Hans-Rainer Hoffmann
Mirko Kreh
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO974119L publication Critical patent/NO974119L/no
Publication of NO974119D0 publication Critical patent/NO974119D0/no
Publication of NO316380B1 publication Critical patent/NO316380B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19974119A 1995-03-17 1997-09-08 Fremgangsmåte for ekstrahering av galantamin, det derved oppnådde galantamin, galeniske preparatformer, anvendelse av galantamin samtfarmas degree ytisk preparatinneholdende galantamin NO316380B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19509663A DE19509663A1 (de) 1995-03-17 1995-03-17 Verfahren zur Isolierung von Galanthamin
PCT/EP1996/001094 WO1996029332A1 (de) 1995-03-17 1996-03-14 Verfahren zur isolierung von galanthamin

Publications (3)

Publication Number Publication Date
NO974119L true NO974119L (no) 1997-09-08
NO974119D0 NO974119D0 (no) 1997-09-08
NO316380B1 NO316380B1 (no) 2004-01-19

Family

ID=7756925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974119A NO316380B1 (no) 1995-03-17 1997-09-08 Fremgangsmåte for ekstrahering av galantamin, det derved oppnådde galantamin, galeniske preparatformer, anvendelse av galantamin samtfarmas degree ytisk preparatinneholdende galantamin

Country Status (23)

Country Link
US (5) US5877172A (no)
EP (2) EP1095656B1 (no)
JP (1) JP3863180B2 (no)
KR (1) KR100427093B1 (no)
CN (1) CN1088460C (no)
AT (2) ATE247473T1 (no)
AU (1) AU707203B2 (no)
CA (1) CA2215351C (no)
CZ (1) CZ294722B6 (no)
DE (3) DE19509663A1 (no)
DK (2) DK0815112T3 (no)
ES (2) ES2206356T3 (no)
HU (1) HU225267B1 (no)
IL (1) IL117371A (no)
MY (1) MY114698A (no)
NO (1) NO316380B1 (no)
NZ (1) NZ304008A (no)
PL (1) PL184238B1 (no)
PT (2) PT815112E (no)
SI (1) SI1095656T1 (no)
SK (1) SK283861B6 (no)
WO (1) WO1996029332A1 (no)
ZA (1) ZA962140B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (en) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906975B4 (de) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Arzneiform zur Behandlung von Alzheimer'scher Demenz
GB9909469D0 (en) * 1999-04-23 1999-06-23 Wilkinson John A Insectidal composition
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
AU2002366555A1 (en) * 2001-12-10 2003-06-23 Washington University Diagnostic for early stage alzheimer's disease
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
CA2516618A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
FR2879599B1 (fr) * 2004-12-16 2007-03-23 Centre Nat Rech Scient Cnrse Utilisation de la chromatographie de partage centrifuge pour la purification de la galanthamine
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
WO2006099635A1 (en) * 2005-03-17 2006-09-21 Ivax Pharmaceuticals S.R.O. Isolation of galanthamine from biological material
US8632800B2 (en) * 2005-05-13 2014-01-21 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
CN1307180C (zh) * 2005-05-24 2007-03-28 天津大学 从石蒜或雪花莲属原料中提取加兰他敏的方法
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
US7446352B2 (en) * 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
JP2009084281A (ja) 2007-09-18 2009-04-23 Ethicon Endo Surgery Inc 術後イレウスの低減のための方法
CN102149398B (zh) * 2008-09-11 2013-12-04 I·B·R·以色列生物科技研究有限公司 雪片莲属鳞茎提取物及其用途
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101602767B (zh) * 2009-05-26 2012-01-11 苏州派腾生物医药科技有限公司 一种加兰他敏的制备方法
DE102009040381A1 (de) 2009-09-07 2011-03-17 Kallimopoulos, Thomas, Dr. Verfahren zur Isolierung von Alkaloiden aus Pflanzen
CN101787028B (zh) * 2010-01-12 2012-01-04 恩施清江生物工程有限公司 一种从忽地笑中提取加兰他敏的方法
CN102050826B (zh) * 2010-12-21 2012-11-14 浙江工业大学 一种分离加兰他敏的方法
BG67337B1 (bg) 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) * 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin

Also Published As

Publication number Publication date
IL117371A0 (en) 1996-07-23
EP1095656A2 (de) 2001-05-02
CN1088460C (zh) 2002-07-31
ES2162035T3 (es) 2001-12-16
ZA962140B (en) 1996-09-16
SI1095656T1 (en) 2004-02-29
JP3863180B2 (ja) 2006-12-27
SK123597A3 (en) 1998-02-04
EP0815112B1 (de) 2001-08-08
CA2215351C (en) 2005-01-11
PT815112E (pt) 2002-01-30
DE59607450D1 (de) 2001-09-13
US20020028802A1 (en) 2002-03-07
US6335328B2 (en) 2002-01-01
EP1095656B1 (de) 2003-08-20
PL322463A1 (en) 1998-02-02
DK1095656T3 (da) 2003-12-08
KR19980703067A (ko) 1998-09-05
JPH11505519A (ja) 1999-05-21
PT1095656E (pt) 2004-01-30
CZ294722B6 (cs) 2005-03-16
IL117371A (en) 2000-01-31
PL184238B1 (pl) 2002-09-30
AU707203B2 (en) 1999-07-08
ATE247473T1 (de) 2003-09-15
KR100427093B1 (ko) 2004-07-31
EP1095656A3 (de) 2001-05-16
HU225267B1 (en) 2006-08-28
SK283861B6 (sk) 2004-03-02
DE19509663A1 (de) 1996-09-19
ES2206356T3 (es) 2004-05-16
MX9707015A (es) 1997-11-29
US5877172A (en) 1999-03-02
US20010001100A1 (en) 2001-05-10
CZ283597A3 (en) 1997-12-17
WO1996029332A1 (de) 1996-09-26
HUP9802234A2 (hu) 1999-02-01
AU5108896A (en) 1996-10-08
NO974119D0 (no) 1997-09-08
CA2215351A1 (en) 1996-09-26
US6194404B1 (en) 2001-02-27
NO316380B1 (no) 2004-01-19
DK0815112T3 (da) 2001-11-12
DE59610680D1 (de) 2003-09-25
US6617452B2 (en) 2003-09-09
EP0815112A1 (de) 1998-01-07
US20030012831A1 (en) 2003-01-16
CN1178533A (zh) 1998-04-08
NZ304008A (en) 1998-09-24
US6573376B2 (en) 2003-06-03
MY114698A (en) 2002-12-31
ATE203993T1 (de) 2001-08-15
HUP9802234A3 (en) 2000-03-28

Similar Documents

Publication Publication Date Title
NO974119L (no) Fremgangsmåte for isolering av galantamin
ATE219893T1 (de) Tabak behandlung
PT616821E (pt) Extraccao de fragrancias
AU7190796A (en) Process and plant for extraction or recovery of acids from solutions of these acids
FI946086A (fi) Menetelmä ja vastavirtauuttoprosessi metallien valmistamiseksi mineraaleista
ATE373722T1 (de) Verfahren zur isolierung von polyhydroxyalkanoaten aus pflanzen
AU5997590A (en) Supercritical fluid and near critical gas extraction of organic solvents from formed articles
HK1013771A1 (en) Ginkgo biloba flavonoid extract which is terpene-free and/or has a high flavonoid heteroside content.
GB2214573A (en) Method for startup of production in an oil well
ZA949180B (en) Hepatoblasts and method of isolating same
ES2076436T3 (es) Procedimiento de recuperacion de teicoplanina.
ATE199153T1 (de) Verfahren zur herstellung von galanthamin und deren derivaten
ATE80418T1 (de) Verfahren zur herstellung eines jasminextraktes und der so gewonnene extrakt.
AU627949B2 (en) Method of extraction of diketones from plant material using organic acid
HUT73638A (en) Process for extracting organic components of natural water and producing pharmaceutical compositions comprising this extract
CS689890A3 (en) Massage ointment containing plant extracts and process for preparingthereof
PL280407A1 (en) Method of obtaining purified plant lecithin
UA32828A (uk) Спосіб ідентифікації присутності келіну у лікарський рослинній сировині
PL289404A1 (en) Method of isolating alkaloids as individual compounds or in groups from materials of plant origin
PL309306A1 (en) Method of preparing a plant material needed to set up plantations of ginkgo biloba l.
PL266798A1 (en) Method of removing volatile organic solvents from postextraction waste water
NO920771D0 (no) Produksjonsmetode ved bruk av sentrifugering
UA27960C2 (uk) Спосіб вилучення германію із надсмольної води коксохімічного виробництва
AU7705687A (en) Method for startup of production in an oil well

Legal Events

Date Code Title Description
MK1K Patent expired